Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

Reply to Wilson et al.

Dickstein Y, Leibovici L, Carmeli Y, Daikos G, Durante-Mangoni E, Friberg LE, Paul M.

Clin Infect Dis. 2019 Nov 17. pii: ciz1100. doi: 10.1093/cid/ciz1100. [Epub ahead of print] No abstract available.

PMID:
31734694
2.

Environmental contamination by carbapenem-resistant Acinetobacter baumannii: The effects of room type and cleaning methods.

Lerner AO, Abu-Hanna J, Carmeli Y, Schechner V.

Infect Control Hosp Epidemiol. 2019 Nov 14:1-6. doi: 10.1017/ice.2019.307. [Epub ahead of print]

PMID:
31722777
3.

Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study.

Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D.

Helicobacter. 2019 Nov 13:e12668. doi: 10.1111/hel.12668. [Epub ahead of print]

PMID:
31721371
4.

Personalized Ertapenem Prophylaxis for Carriers of Extended-spectrum β-Lactamase-producing Enterobacteriaceae Undergoing Colorectal Surgery.

Nutman A, Temkin E, Harbarth S, Carevic B, Ris F, Fankhauser-Rodriguez C, Radovanovic I, Dubinsky-Pertzov B, Cohen-Percia S, Kariv Y, Buchs N, Schiffer E, Fallach N, Klausner J, Carmeli Y; Resistance in Gram-negative Organisms: Studying Intervention Strategies (R-GNOSIS) WP4 Study Group.

Clin Infect Dis. 2019 Jun 19. pii: ciz524. doi: 10.1093/cid/ciz524. [Epub ahead of print]

PMID:
31613316
5.

The possibility of transmitting infections with vaginal ultrasound probes: why the guidelines must be met

Schwaber M, Vaturi A, Rubinovitch B, Ben-David D, Solter E, Carmeli Y.

Isr Med Assoc J. 2019 Aug 1;21(8):568-569. No abstract available.

6.

Antimicrobial use trends, Israel, 2012 to 2017.

Dickstein Y, Temkin E, Ben-David D, Carmeli Y, Schwaber MJ.

Euro Surveill. 2019 Aug;24(34). doi: 10.2807/1560-7917.ES.2019.24.34.1900022.

7.

Likelihood of persistent carriage of carbapenem-resistant Acinetobacter baumannii on readmission in previously identified carriers.

Nutman A, Lerner A, Fallach N, Schwartz D, Carmeli Y.

Infect Control Hosp Epidemiol. 2019 Oct;40(10):1188-1190. doi: 10.1017/ice.2019.210. Epub 2019 Aug 5.

PMID:
31379306
8.

External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.

Machuca I, Gutiérrez-Gutiérrez B, Rivera-Espinar F, Cano A, Gracia-Ahufinger I, Guzman-Puche J, Marfil-Pérez E, Pérez-Nadales E, Castón JJ, Bonomo RA, Carmeli Y, Paterson D, Pascual Á, Martínez-Martínez L, Rodríguez-Baño J, Torre-Cisneros J; REIPI/ESGBIS/INCREMENT Group.

Int J Antimicrob Agents. 2019 Oct;54(4):442-448. doi: 10.1016/j.ijantimicag.2019.07.017. Epub 2019 Aug 1.

PMID:
31377343
9.

The association between implementation of second-tier prevention practices and CLABSI incidence: A national survey.

Ben-David D, Vaturi A, Solter E, Temkin E, Carmeli Y, Schwaber MJ; Israel CLABSI Prevention Working Group.

Infect Control Hosp Epidemiol. 2019 Oct;40(10):1094-1099. doi: 10.1017/ice.2019.190. Epub 2019 Jul 24.

PMID:
31339089
10.

Trends in antimicrobial resistance in Israel, 2014-2017.

Dickstein Y, Temkin E, Ish Shalom M, Schwartz D, Carmeli Y, Schwaber MJ.

Antimicrob Resist Infect Control. 2019 Jun 4;8:96. doi: 10.1186/s13756-019-0535-1. eCollection 2019.

11.

Estimating the association between antibiotic exposure and colonization with extended-spectrum β-lactamase-producing Gram-negative bacteria using machine learning methods: a multicentre, prospective cohort study.

Tacconelli E, Górska A, De Angelis G, Lammens C, Restuccia G, Schrenzel J, Huson DH, Carević B, Preoţescu L, Carmeli Y, Kazma M, Spanu T, Carrara E, Malhotra-Kumar S, Gladstone BP.

Clin Microbiol Infect. 2019 May 23. pii: S1198-743X(19)30247-2. doi: 10.1016/j.cmi.2019.05.013. [Epub ahead of print]

PMID:
31128285
12.

Zero or More: Methodological Challenges of Counting and Estimating Deaths Related to Antibiotic-resistant Infections.

Temkin E, Carmeli Y.

Clin Infect Dis. 2019 Nov 13;69(11):2029-2034. doi: 10.1093/cid/ciz414.

PMID:
31102400
13.

Microbiological diagnostics of bloodstream infections in Europe-an ESGBIES survey.

Idelevich EA, Seifert H, Sundqvist M, Scudeller L, Amit S, Balode A, Bilozor A, Drevinek P, Kocak Tufan Z, Koraqi A, Lamy B, Mareković I, Miciuleviciene J, Müller Premru M, Pascual A, Pournaras S, Saegeman V, Schønheyder HC, Schrenzel J, Strateva T, Tilley R, Wiersinga WJ, Zabicka D, Carmeli Y, Becker K; ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES).

Clin Microbiol Infect. 2019 Nov;25(11):1399-1407. doi: 10.1016/j.cmi.2019.03.024. Epub 2019 Apr 10.

PMID:
30980927
14.

Droplet aerosol dissemination of carbapenem-resistant Acinetobacter baumannii surrounding ventilated patients.

Mousa M, Schwartz D, Carmeli Y, Nutman A.

Infect Control Hosp Epidemiol. 2019 Mar;40(3):365-367. doi: 10.1017/ice.2018.335. Epub 2019 Feb 18.

PMID:
30773156
15.

A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial.

Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, Zanichelli V, Kapel N, Bellanger A, Olearo F, Duval X, Armand-Lefevre L, Carmeli Y, Bonten M, Fantin B, Harbarth S; R-Gnosis WP3 study group.

Clin Microbiol Infect. 2019 Jul;25(7):830-838. doi: 10.1016/j.cmi.2018.12.009. Epub 2019 Jan 4.

16.

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group .

Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.

PMID:
30462182
17.

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility.

Lellouche J, Schwartz D, Elmalech N, Ben Dalak MA, Temkin E, Paul M, Geffen Y, Yahav D, Eliakim-Raz N, Durante-Mangoni E, Iossa D, Bernardo M, Daikos GL, Skiada A, Pantazatou A, Antoniadou A, Mouton JW, Carmeli Y; AIDA study group.

Clin Microbiol Infect. 2019 Jun;25(6):711-716. doi: 10.1016/j.cmi.2018.09.014. Epub 2018 Oct 4.

PMID:
30291971
18.

Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae and the Risk of Surgical Site Infection After Colorectal Surgery: A Prospective Cohort Study.

Dubinsky-Pertzov B, Temkin E, Harbarth S, Fankhauser-Rodriguez C, Carevic B, Radovanovic I, Ris F, Kariv Y, Buchs NC, Schiffer E, Cohen Percia S, Nutman A, Fallach N, Klausner J, Carmeli Y; R-GNOSIS WP4 Study Group.

Clin Infect Dis. 2019 May 2;68(10):1699-1704. doi: 10.1093/cid/ciy768.

PMID:
30204851
19.

Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study.

Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y; DRIVE-AB Consortium.

Lancet Glob Health. 2018 Sep;6(9):e969-e979. doi: 10.1016/S2214-109X(18)30278-X.

20.

Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, Guzner-Gur H, Santo E, Halpern Z, Carmeli Y, Maharshak N.

United European Gastroenterol J. 2018 Jun;6(5):773-780. doi: 10.1177/2050640617750809. Epub 2017 Dec 21.

21.

Success of a National Intervention in Controlling Carbapenem-resistant Enterobacteriaceae in Israel's Long-term Care Facilities.

Ben-David D, Masarwa S, Fallach N, Temkin E, Solter E, Carmeli Y, Schwaber MJ; Israel LTCF CRE Working Group.

Clin Infect Dis. 2019 Mar 5;68(6):964-971. doi: 10.1093/cid/ciy572.

PMID:
29986007
22.

Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodríguez-Baño J, Venditti M; REIPI/ESGBIS/INCREMENT investigators.

Int J Antimicrob Agents. 2018 Nov;52(5):577-585. doi: 10.1016/j.ijantimicag.2018.06.018. Epub 2018 Jun 30.

PMID:
29969692
23.

The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model.

Almagor J, Temkin E, Benenson I, Fallach N, Carmeli Y; DRIVE-AB consortium.

PLoS One. 2018 May 14;13(5):e0197111. doi: 10.1371/journal.pone.0197111. eCollection 2018.

24.

The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.

Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M; AIDA Study Group.

Clin Infect Dis. 2018 Nov 28;67(12):1815-1823. doi: 10.1093/cid/ciy371.

PMID:
29718143
25.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
26.

Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.

Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y.

Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1281-1288. doi: 10.1007/s10096-018-3247-1. Epub 2018 Apr 7.

PMID:
29627951
27.

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):660-667. doi: 10.1017/ice.2018.63. Epub 2018 Apr 5.

PMID:
29618394
28.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
29.

Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients.

Manistarski M, Levin D, Dvir R, Berger-Achituv S, Rosenfeld Keidar H, Grisaru-Soen G, Carmeli Y, Elhasid R.

Pediatr Infect Dis J. 2018 Jul;37(7):649-653. doi: 10.1097/INF.0000000000001920.

PMID:
29373475
30.

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group.

Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.

PMID:
29276051
31.

Israeli National Policy for Carbapenem-Resistant Enterobacteriaceae Screening, Carrier Isolation and Discontinuation of Isolation.

Solter E, Adler A, Rubinovitch B, Temkin E, Schwartz D, Ben-David D, Masarwa S, Carmeli Y, Schwaber MJ.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):85-89. doi: 10.1017/ice.2017.211. Epub 2017 Dec 15.

PMID:
29241475
32.

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group.

Clin Infect Dis. 2017 Oct 30;65(10):1615-1623. doi: 10.1093/cid/cix606.

33.
34.

Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply.

Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J.

Lancet Infect Dis. 2017 Oct;17(10):1020-1021. doi: 10.1016/S1473-3099(17)30522-4. No abstract available.

PMID:
28948921
35.

Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study.

Bassal R, Markovich MP, Weil M, Shinar E, Carmeli Y, Dan M, Sofer D, Mendelson E, Cohen D, Shohat T.

Epidemiol Infect. 2017 Oct;145(14):2890-2895. doi: 10.1017/S0950268817002126. Epub 2017 Sep 14.

PMID:
28903797
36.

Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.

Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J; ESGBIS/REIPI/INCREMENT Group.

Int J Antimicrob Agents. 2017 Nov;50(5):664-672. doi: 10.1016/j.ijantimicag.2017.08.005. Epub 2017 Aug 3.

PMID:
28782704
37.

Does Acinetobacter baumannii Serve as a Source for blaNDM Dissemination into Enterobacteriaceae in Hospitalized Patients?

Adler A, Glick R, Lifshitz Z, Carmeli Y.

Microb Drug Resist. 2018 Mar;24(2):150-153. doi: 10.1089/mdr.2016.0330. Epub 2017 Jun 30.

PMID:
28665176
38.

Incidence and Risk Factors for Community and Hospital Acquisition of Clostridium difficile Infection in the Tel Aviv Sourasky Medical Center.

Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y.

Infect Control Hosp Epidemiol. 2017 Aug;38(8):912-920. doi: 10.1017/ice.2017.82. Epub 2017 May 31.

PMID:
28558856
39.

Evolution and dissemination of the Klebsiella pneumoniae clonal group 258 throughout Israeli post-acute care hospitals, 2008-13.

Adler A, Lifshitz Z, Gordon M, Ben-David D, Khabra E, Masarwa S, Zion O, Schwaber MJ, Carmeli Y.

J Antimicrob Chemother. 2017 Aug 1;72(8):2219-2224. doi: 10.1093/jac/dkx135.

PMID:
28486697
40.

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.

Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.

PMID:
28442293
41.

Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control.

Friedman ND, Carmeli Y, Walton AL, Schwaber MJ.

Infect Control Hosp Epidemiol. 2017 May;38(5):580-594. doi: 10.1017/ice.2017.42. Epub 2017 Mar 15. Review. Erratum in: Infect Control Hosp Epidemiol. 2017 Sep;38(9):1136.

PMID:
28294079
42.

Fixed time interval compared with on-demand oral analgesia protocols for post-caesarean pain: a randomised controlled trial.

Yefet E, Taha H, Salim R, Hasanein J, Carmeli Y, Schwartz N, Nachum Z.

BJOG. 2017 Jun;124(7):1063-1070. doi: 10.1111/1471-0528.14546. Epub 2017 Feb 25.

43.
44.

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.

J Antimicrob Chemother. 2017 Mar 1;72(3):906-913. doi: 10.1093/jac/dkw513.

45.

EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol.

Babu Rajendran N, Gladstone BP, Rodríguez-Baño J, Sifakis F, Voss A, Carmeli Y, Burkert FR, Gkolia P, Tacconelli E.

BMJ Open. 2017 Jan 5;7(1):e013634. doi: 10.1136/bmjopen-2016-013634. Erratum in: BMJ Open. 2017 Jan 27;7(1):e013634corr1.

46.

Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01964-16. doi: 10.1128/AAC.01964-16. Print 2017 Feb.

47.

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group.

Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18.

PMID:
27866944
48.

Gentamicin- and Ciprofloxacin-Resistant Enterobacteriaceae in Cattle Farms in Israel: Risk Factors for Carriage and the Effect of Microbiological Methodology on the Measured Prevalence.

Adler A, Sturlesi N, Fallach N, Zilberman-Barzilai D, Hussein O, Blum SE, Klement E, Schwaber MJ, Carmeli Y.

Microb Drug Resist. 2017 Jul;23(5):660-665. doi: 10.1089/mdr.2016.0052. Epub 2016 Nov 9.

PMID:
27828758
49.

Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel.

Miller-Roll T, Na'amnih W, Cohen D, Carmeli Y, Adler A.

Diagn Microbiol Infect Dis. 2016 Dec;86(4):450-454. doi: 10.1016/j.diagmicrobio.2016.08.021. Epub 2016 Aug 26.

PMID:
27638350
50.

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group.

Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024. Erratum in: Mayo Clin Proc. 2016 Dec;91(12 ):1843.

PMID:
27712635

Supplemental Content

Loading ...
Support Center